On or around 11/13/2019 (Date of last review)
Filing Date: August 05, 2019
According to the Complaint, Curaleaf purports to operate as an integrated medical and wellness cannabis operator in the United States.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration ("FDA"); and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On November 7, 2019, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel.
Company & Securities Information
Defendant: Curaleaf Holdings, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: CURLF
Company Market: OTC-BB
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Michael Skibbe, et al. v. Curaleaf Holdings, Inc., et al.